PARD (Poniard Pharmaceuticals) ROCE %: -236.86% (As of Sep. 2011)


What is Poniard Pharmaceuticals ROCE %?

Poniard Pharmaceuticals PARD ROCE % is -236.86% as of Sep. 2011.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Poniard Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2011 was -236.86%.

Poniard Pharmaceuticals  (OTCPK:PARD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Poniard Pharmaceuticals ROCE % Related Terms

Poniard Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals ROCE % Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -70.73 -46.35 -61.16 -80.55 -116.15

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -108.00 -131.22 -123.35 -163.00 -236.86

Poniard Pharmaceuticals ROCE % Calculation

Poniard Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2010 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2010 )  (A: Dec. 2009 )(A: Dec. 2010 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2010 )  (A: Dec. 2009 )(A: Dec. 2010 )
=-26.332/( ( (52.442 - 17.127) + (11.643 - 1.616) )/ 2 )
=-26.332/( (35.315+10.027)/ 2 )
=-26.332/22.671
=-116.15 %

Poniard Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2011 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2011 )  (Q: Jun. 2011 )(Q: Sep. 2011 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2011 )  (Q: Jun. 2011 )(Q: Sep. 2011 )
=-14.992/( ( (9.989 - 2.087) + (7.736 - 2.979) )/ 2 )
=-14.992/( ( 7.902 + 4.757 )/ 2 )
=-14.992/6.3295
=-236.86 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2011) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -236.86% mean?
Poniard Pharmaceuticals (PARD) has a ROCE % of -236.86% as of Sep. 2011.
Is Poniard Pharmaceuticals' ROCE % too high?
Poniard Pharmaceuticals' current ROCE % is -236.86%.
How does Poniard Pharmaceuticals' ROCE % compare to OBMP and NSPX?
Poniard Pharmaceuticals' ROCE % of -236.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Poniard Pharmaceuticals's current ROCE % is -236.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current ROCE % of -236.86%. The current ROCE % is -236.86%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current ROCE % is -236.86% as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.